Kathleen M. Sanzo


Kathleen M. Sanzo centers her practice on regulatory and compliance issues connected to products regulated by the US Food and Drug Administration (FDA). She leads and counsels clients on matters relating to prescription, OTC drug, and biotechnology products clinical testing; food, dietary supplement, and cosmetic product manufacture, approval, marketing, and distribution; device promotion and labeling issues; food, drug, and device compliance matters; and all consumer product issues regulated by the US Consumer Product Safety Commission (CPSC) and state enforcement agencies.


4/5/2019 - C.B.D.: The Risks vs. the Reward, Baking Business

4/5/2019 - FDA's Puzzle: Measuring How DSHEA Fits for Supplement Industry Oversight, The Pink Sheet

3/22/2019 - Attorneys: CBD Concentration, Supply Chains Will Be Questioned by FDA During April Public Comments

1/3/2019 - Morgan Lewis Launches As Prescribed Blog on Issues Facing Pharma, Biotech Sectors

10/15/2018 - Industry Should Seek Guidance, Supply-Chain Checks for California Cruelty-Free Compliance, Rose Sheet

9/5/2018 - FDA Focus: What Morgan Lewis' Practice Chair Is Watching, Law360

April 2018 - Life Sciences 2018: Regulatory Analysis, Who's Who Legal

12/12/2017 - Morgan Lewis Advises Repros Therapeutics in Sale to Allergan

5/15/2017 - More than 35 Morgan Lewis Lawyers Named Top Women in the Law by Best Lawyers

6/20/2016 - Morgan Lewis Forum to Highlight Global Regulatory and Transactional Considerations for Growing Life Sciences Companies

View more...